SCHEMBL953862

SCHEMBL953862

O=[C]C1=Cc2cccc3cccc1c23

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
MAPT P10636 2/20 0.56
ALDH1A1 P00352 6/20 0.45
MCL1 Q07820 2/20 0.45
CES2 O00748 1/20 0.45
BCHE P06276 1/20 0.45
CES1 P23141 1/20 0.45
S100A4 P26447 1/20 0.41
PABPC1 P11940 3/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
CYP3A4 P08684 2/20 0.39
DNMT1 P26358 2/20 0.39
HSD17B10 Q99714 5/20 0.38
TSHR P16473 3/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TYMS P04818 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31291412 0.80 MAPK1 (0.52) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL4922451 0.80 MAPK1 (0.52) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL9347855 0.76 GPR84 (0.38) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL5430435 0.76 MEN1 (0.61) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL28571360 0.76 MEN1 (0.61) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL779663 0.73 MAPK1 (0.53) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL58539 0.72 MAPK1 (0.57) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL30184802 0.72 MEN1 (1.00) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL16225115 0.72 MEN1 (1.00) MAPK1MEN1KMT2AMAPTALDH1A1
SCHEMBL3124182 0.72 MEN1 (0.51) MAPK1MEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11702557-B2 Ink composition for manufacturing organic semiconductor device DAICEL CORPORATION (JP) 2023-07-18 US disclosed
EP-3958335-A1 INK COMPOSITION FOR PRODUCING ORGANIC SEMICONDUCTOR DEVICE Daicel Corporation (JP) 2022-02-23 EP disclosed
CN-113692653-A Ink composition for manufacturing organic semiconductor device 株式会社大赛璐 2021-11-23 CN disclosed
US-20210246325-A1 INK COMPOSITION FOR MANUFACTURING ORGANIC SEMICONDUCTOR DEVICE DAICEL CORPORATION (JP) 2021-08-12 US disclosed
EP-3855520-A1 INK COMPOSITION FOR MANUFACTURING ORGANIC SEMICONDUCTOR DEVICE Daicel Corporation (JP) 2021-07-28 EP disclosed
CN-112771684-A Ink composition for manufacturing organic semiconductor device 株式会社大赛璐 2021-05-07 CN disclosed
WO-2020213460-A1 INK COMPOSITION FOR PRODUCING ORGANIC SEMICONDUCTOR DEVICE 株式会社ダイセル 2020-10-22 WO disclosed
WO-2020059626-A1 INK COMPOSITION FOR MANUFACTURING ORGANIC SEMICONDUCTOR DEVICE 株式会社ダイセル 2020-03-26 WO disclosed
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-1752457-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-02-14 EP disclosed
WO-2007004749-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-11 WO disclosed
EP-1287044-A4 STERILE PHOTOCHROMIC HYDROPHILIC CONTACT LENSES NOVARTIS AG (CH) 2004-12-15 EP disclosed
US-20030149027-A1 1,5-benzodiazepine compounds, their production and use OI SATORU (JP) 2003-08-07 US disclosed
EP-1287044-A1 STERILE PHOTOCHROMIC HYDROPHILIC CONTACT LENSES Novartis AG (CH) 2003-03-05 EP disclosed
EP-1123928-A1 1,5-BENZODIAZEPINE COMPOUNDS, PROCESS FOR PRODUCING THE SAME, AND MEDICINE Takeda Chemical Industries, Ltd. (JP) 2001-08-16 EP disclosed
WO-2001030866-A1 STERILE PHOTOCHROMIC HYDROPHILIC CONTACT LENSES WESLEY JESSEN CORPORATION (US) 2001-05-03 WO disclosed
US-6162828-A IMMUNOLOGY; ANTIINFLAMMATORY AGENTS; ANTITUMOR AGENTS; BONE DISORDERS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-12-19 US disclosed
EP-0820464-A2 CYSTEINE PROTEASE INHIBITOR Takeda Chemical Industries, Ltd. (JP) 1998-01-28 EP disclosed
WO-1996030395-A2 CYSTEINE PROTEASE INHIBITOR TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149027-A1 1,5-benzodiazepine compounds, their production and use GABRA1, GABRA5, CNR1 MAPK1 1634/4885MEN1 3395/4885KMT2A 1490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.